Japan Approves the World’s First Treatment Made With Reprogrammed Human Cells

ReHeart was approved in Japan, japan approved ReHeart, a cardiac cell-sheet transplant therapy for severe heart failure.

ReHeart transplant is performed by attaching three sheets of cardiomyocytes to the heart surface, three sheets of cardiomyocytes are attached to the heart surface via surgery in the left chest.

Clinical study included eight patients and showed improvement in four patients with VO2 peak rising over 10% at 52 weeks, In a national multicenter study of eight severe heart failure patients, four showed improvement including VO2 peak increases over 10% at 52 weeks.

Amshepri was approved in Japan, japan approved Amusepri (generic name: laguneprocell) from Sumitomo Pharma and Racthera for Parkinson's disease motor symptoms.

Amshepri transplant is performed by injecting precursor dopaminergic progenitor cells into the brain through drilled skull holes and three delivery routes, progenitor cells derived from donor iPS cells are transplanted into the brain via minimally invasive surgery through small skull holes and three delivery routes.